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Abstract
Background: Flaxseed has received attention for its anti-inflammatory and antioxidant role. The present study
hypothesizes if flaxseed added to a weight loss diet could improve the lipid and metabolic profiles and decrease
risk factors related to cardiovascular disease.
Methods: In a prospective, single blinded 42 days protocol, subjects were allocated into two groups with low
carbohydrates intake: GriceLC (35% of carbohydrate and 60g of raw rice powder per day) and GflaxLC (32% of
carbohydrate and 60g of flaxseed powder per day). Blood pressure, anthropometric measures and serum levels of
isoprostane, C-reactive protein, Tumor Necrosis Factor-alpha, glucose, lipidic profile, uric acid, adiponectin, leptin
and insulin were measured at baseline and at the end of interventions. Serum and urinary enterodiol and
enterolactione were also measured.
Results: A total of 27 men with cardiovascular risk factors were evaluated, with mean age of 33 ± 10 years to
GriceLC and 40 ± 9 years to GflaxLC. Both groups experienced weight loss and systolic blood pressure reduction.
A decrease in inflammatory markers (CRP and TNF-α) was observed after flaxseed intake (mean decrease of 25%
and 46% for GflaxLC respectively). All groups also showed improvement in levels of total cholesterol, LDL-c, uric acid
and adiponectin. Only GflaxLC group showed a decrease in triglyceride levels.
Conclusion: This study suggests that flaxseed added to a weight loss diet could be an important nutritional
strategy to reduce inflammation markers such as CRP and TNF-α.
Trial registration: ClinicalTrials.gov NCT02132728.
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Background
Obesity is associated with altered inflammatory markers
such as high blood levels of C-Reactive Protein (CRP)
and Tumor Necrosis Factor-alpha (TNF-α) [1,2] and
reduced of adiponectin [3,4]. This can contribute to
incidence of diseases once adiponectin, in high levels,
has been associated with a lower risk of cardiovascular
death [5,6].
The most common approach for treatment of obesity
includes hypocaloric diets resulting in energy deficit as-
sociated with restriction of certain food groups, such as
those containing high-carbohydrate [7].
Additionally,a recent literature review indicates
more than 1000 weight loss diets published. While
some eliminate one or more groups of food, others
recommend the intake of specific food, based on dif-
ferent effects on the metabolism [8]. Thus, by adding
or removing a certain food seems to be possible that
weight loss diets manage inflammation, as a modifi-
able risk factor [9-11].
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In this setting, flaxseed is well known for its antioxi-
dant, lipid and glycemic lowering actions [12] that
have been attributed to its components linolenic acid,
dietary fibers, lignans and its degradation products [13].
This study evaluates if flaxseed added to a weight loss diet
generates improvement on nutritional and inflammatory
markers.
Methods
Ethics statement
This study was approved by the Ethics Committee of
Ribeirão Preto Medical School of São Paulo University
(number 4244/2007) and conducted according to
Declaration of Helsinki. All participants provided writ-
ten informed consent.
Table 1 Nutritional composition of diet according to 24-hours food recall in both groups and times assessed
Variable Time Group
GriceLC (n = 13) GflaxLC (n = 14)
Energy (kcal/day) Initial 3869 ± 1012*a 3665 ± 713*a
Final 1765 ± 193 1578 ± 213
Mean difference −2104 ± 997 −2154 ± 738
Carbohydrate (g/d) Initial 451 ± 118*a 478 ± 73*a
Final 201 ± 32 159 ± 28
Mean difference −188 ± 214 −318 ± 76
Protein (g/d) Initial 187 ± 53*a 152 ± 55*a
Final 122 ± 22 118 ± 23
Mean difference −65 ± 59 −34 ± 57
Fat (g/d) Initial 135 ± 62*a 127 ± 37*a
Final 54 ± 15 55 ± 11
Mean difference −81 ± 71 −75 ± 37
MUFA (g/d) Initial 43 ± 20*a 42 ± 12*a
Final 26 ± 9 19 ± 6
Mean difference −17 ± 26 −20 ± 17
PUFA (g/d) Initial 25 ± 13*a 24 ± 9
Final 12 ± 6 24 ± 5
Mean difference −6 ± 14 −0.8 ± 10
ω-3 (g/d) Initial 3 ± 2 4 ± 3*a
Final 3 ± 2 14 ± 2
Mean difference −0.3 ± 2.5 10 ± 3**b
ω-6 (g/d) Initial 22 ± 11*a 22 ± 8*a
Final 9 ± 5 10 ± 4
Mean difference −13 ± 13 −12 ± 9
SFA (g/d) Initial 51 ± 27*a 51 ± 16*a
Final 13 ± 3 12 ± 3
Mean difference −35 ± 32 −38 ± 14
Dietary cholesterol (mg/d) Initial 569 ± 220*a 583 ± 313*a
Final 267 ± 67 248 ± 59
Mean difference −334 ± 254 −335 ± 322
Total fiber (g/d) Initial 41 ± 15*a 42 ± 14
Final 26 ± 6 41 ± 5
Mean difference −15 ± 15 −7 ± 20
Data are expressed in mean ± Standard Deviation. n, number of subjects; Kcal/day, kilocalorie per day; g/d, grams per day; mg/d, milligrams per day;
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids ω-3, omega 3 fatty acids, ω-6, omega 6 fatty acids.
**Significant difference between initial and final times (p < 0.01).
aMean-comparison t test, paired data. Comparisons between initial and final times assessed.
bTwo-group mean comparison t test. Comparisons between the mean differences across initial and final times assessed, in both groups.
Cassani et al. Nutrition Journal 2015, 14:5 Page 2 of 8
http://www.nutritionj.com/content/14/1/5
Design of the study
A prospective single blind and interventional study in
which volunteers were divided into two groups, followed
for 42 days and received similar proportions of carbohy-
drates plus brown flaxseed or rice raw powder. Participant
recruitment and follow-up occurred between March 5th
and July 25th, 2007.
Participants and study settings
Subjects were recruited from a large manufacturing
company at the city of Itu, São Paulo, Brazil.
The inclusion criteria were male gender, age between
20-60 years-old and at least three of the following
cardiovascular risk factors: waist circumference ≥ 90 cm
[14]; Body Mass Index (BMI) ≥ 25 kg/m2 [15]; fasting
total cholesterol ≥ 200 mg/dL, low density lipoprotein
cholesterol (LDL-c) ≥ 130 mg/dL, high density lipopro-
tein cholesterol (HDL-c) < 40 mg/dL, triglycerides ≥ 150
mg/dL [16]; glycemia ≥100 mg/dL [14]; systolic blood
pressure ≥140 mm/Hg and/or diastolic blood pressure ≥
90 mm/Hg [17]. The exclusion criteria were use of lipid
lowering or weight loss medication in the last three
months.
Interventions
Diet plans were provided to each group as following:
GriceLC group received 35% carbohydrate, 46% fat, 19%
protein and 60g of raw rice powder/day. GflaxLC group
received 32% carbohydrate, 47% fat, 21% protein and
60 g of flaxseed powder/day. Table 1 shows the nutrient
composition of diets.
Figure 1 Study flow chart.
Table 2 Blood pressure and anthropometric data,
according to study group and time of assessment
Group
Variable Time GriceLC (n = 13) GflaxLC (n = 14)
Systolic BP Initial 134 ± 9.2* 139 ± 20.3*
Final 125 ± 8.1 127 ± 17
Mean
difference
−9 ± 12 −12 ± 11
Diastolic BP Initial 80 ± 7.7 83 ± 13.5
Final 77 ± 8.2 81 ± 8.9
Mean
difference
−3 ± 10 −2 ± 11
Weight (Kg) Initial 94,9 ± 11,2* 96 ± 14*
Final 88,1 ± 10,2 90 ± 14
Mean
difference
−7 ± 2 −6 ± 6
BMI (kg/m2) Initial 32,1 ± 2,8* 32 ± 3*
Final 29,8 ± 2,5 30 ± 4
Mean
difference
−2.3 ± 0.7 −1.9 ± 2
Waist circumference (cm) Initial 107 ± 8* 108 ± 8*
Final 93 ± 6 95 ± 8
Mean
difference
−14 ± 3 −13 ± 4
Hip circumference (cm) Initial 108 ± 7* 106 ± 8*
Final 104 ± 6 103 ± 7
Mean
difference
−4 ± 2 −2 ± 2*b
Subscapular. skinfold (mm) Initial 41 ± 13* 38 ± 11*
Final 18 ± 3 20 ± 5
Mean
difference
−23 ± 11 −18 ± 7
Supra iliac skinfold (mm) Initial 33 ± 12* 37 ± 9*
Final 15,2 ± 4 16 ± 4
Mean
difference
−17 ± 8 −21 ± 10
Abdominal skinfold (mm) Initial 65 ± 5* 66 ± 3*
Final 23 ± 4 25 ± 5
Mean
difference
−42 ± 4 −40 ± 6
Data are expressed in mean± Standard Deviation. n, number of subjects; BP,
blood pressure (mmHg); BMI, body mass index, kg/m2, kilogram per meter squared.
*Significant difference between initial and final times (p < 0.05).
bTwo-group mean comparison t test. Comparisons between the mean
differences across initial and final times assessed, in both groups.
Cassani et al. Nutrition Journal 2015, 14:5 Page 3 of 8
http://www.nutritionj.com/content/14/1/5
Flaxseed and raw rice were crushed weekly by minimal
particle type mill. Also, sieves were used for optimal
grinding grain with a size of 250 mm/micrometers
DLF 1® W22060®, 20353836 series (Universal Buhler,
CMBH, Germany) and Vibrating MAQ® model 2221,
10.04 series (Bertel® Brazil). After crushing flaxseed and
raw rice, they were weighed in a semi-analytical scale,
OHAUS® (Germany) and packed in suitable plastic bags.
The following meals were made at the company:
breakfast, light meal, lunch and afternoon snack. Dinner,
evening snack and weekend meals were performed at
home. The addition of flaxseed or raw rice powder was
made in the light meal (40 g added to milk) and lunch
(20 g added to baked beans). Regarding to blinding
method, only a research member who did not have ac-
cess to data knew what each volunteer received, rice or
flaxseed.
Dietary assessment
Dietary intake was assessed twice by 24-hour food recall,
in a week day and in a weekend day. Nutrient compos-
ition of the diets at baseline and during the nutritional
intervention was performed using the Diet PRO® Pro-
gram, version 4 (Agromídia Based Technology Com-
pany®, Viçosa, Brazil, MG).
Physical examination
Height and weight were measured according to institu-
tional protocols [18]. BMI was classified as suggested
by World Health Organization (WHO) [15]. Suprailiac,
subscapular and abdominal skinfolds were evaluated
using a compass Lange® (Beta Technology Incorporated,
USA). Waist and hip circumferences were also analyzed
[19]. Blood pressure was measured by an automated de-
vice (OMRON® HEM 705-CP, Japan) following current
guidelines [20].
Biochemical assessments
Blood was collected after 12-hour fasting for biochemical
assessments: total cholesterol and fractions (LDL-c and
HDL-c), triglycerides, glucose, insulin, homeostasis model
assessment for β-cell function (HOMA-β) and insulin re-
sistance (HOMA-IR), uric acid, as well as for evaluation of
inflammatory markers (CRP, TNF-α), serum isoprostane
and hormones (leptin and adiponectin).
Determination of total cholesterol, HDL-c, triglyceride,
glucose and uric acid was performed by enzymatic
method, with HITACHI® 912 - ROCHE (Japan). Re-
agents used were: CHOD-PAP, ROCHE (Japan) for total
cholesterol and triglyceride; Bioclin K071 (Japan) for
HDL-c; GOD-PAD (Roche) (Japan) for glucose and Uric
Acid Plus (URICASE) (Japan) for uric acid. Friedewald
equation was used to determine LDL-c [21].
IMMULITE 1000® SYSTEMS - Siemens Medical Solu-
tions Diagnostics (Los Angeles, USA) was used to detect
insulin by chemiluminescence. HOMA indexes were ob-
tained by equations disclosed in literature [22].
Immunoturbidimetric assay was performed with the
COBAS® MIRAPLUS - ROCHE (USA) with 0.03 mg/L
as detection limit and intra assay coefficient of variation
Table 3 Fasting biochemical data, according to study
group and time of assessment
Variable Time Group
GriceLC (n = 13) GflaxLC (n = 14)
Glycemia (mg/dL) Initial 98 ± 16 90 ± 15
Final 91 ± 12 88 ± 10
Mean
difference
−7 ± 13 −1 ± 16
Total cholesterol (mg/dL) Initial 205 ± 36* 223 ± 50*
Final 180 ± 31 186 ± 41
Mean
difference
−25 ± 21 −37 ± 37
LDL-c (mg/dL) Initial 135 ± 50* 151 ± 59*
Final 110 ± 26 116 ± 37
Mean
difference
−25 ± 39 −31 ± 51
HDL-c (mg/dL) Initial 44 ± 9 42 ± 5*
Final 42 ± 7 38 ± 4
Mean
difference
−2 ± 6 −4 ± 5
Triacylglycerol(&) (mg/dL) Initial 241 ± 264 215 ± 110*
Final 144 ± 56 153 ± 83
Mean
difference
−97 ± 252 −62 ± 71
Uric acid (mg/dL) Initial 7 ± 1* 7 ± 2*
Final 6 ± 1 6 ± 3
Mean
difference
−0.5 ± 0.7 −0.7 ± 0.8
Insulin(&) (micro IU/mL) Initial 18 ± 14* 12 ± 8
Final 7 ± 5 9 ± 5
Mean
difference
−11 ± 13 −3 ± 8
HOMA beta(&) Initial 60 ± 40* 49 ± 55
Final 25 ± 16 31 ± 18
Mean
difference
−35 ± 40 −18 ± 54
HOMA IR(&) Initial 5 ± 5* 3 ± 1
Final 2 ± 1 2 ± 1
Mean
difference
−3 ± 4 −1 ± 1
Data are expressed in mean ± Standard Deviation. n, number of subjects;
HOMA-IR, homeostasis model assessment of insulin resistance; LDL-c, low-density
lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol.
*Significant difference between initial and final times (p < 0.05).
&Variable analyzed with log transformation.
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of 10% to measure ultra-sensitive CRP. The reagent
used was TURB-PCR, manufacturer ERBRAM Prods.
Laboratory Ltda. (São Paulo, Brazil). TNF-α, leptin
and adiponectin were measured by enzyme immuno-
assay method, using LINCOPLEX-LUMINEX® kits,
Millipore Corporation (USA). Determination of 8-Iso-
Prostaglandin F2a (serum isoprostane) was performed
by enzyme immunoassay kits, ASSAY DESIGNS® Inc,
(USA).
Serum and urinary enterolignans, enterodiol (END)
and enterolactone (ENL) were assessed by high perform-
ance liquid chromatography with Shimadzu model LC
10AD® (Shimadzu Corporation, Japan).
Statistical methods
Student's t-test for paired data was used for compar-
isons between initial (day zero) and final (day 42)
assessments. The mean differences between final and
initial times of data collection in both groups were
compared by two-group mean comparison test (t test)
or Wilcoxon rank-sum test when appropriate. When
assumption of normality of data was rejected, vari-
able was normalized after logarithmic transformation
or non-parametric tests were used. The analyses were
conducted with STATA/IC, version 11.2 (StataCorp
LP, USA). The significance level used for the tests
was 5%.
Results
Participant flow and baseline characteristics
The selection flow of subjects was summarized in Figure 1.
From 93 employees evaluated, 27 were allocated as follow:
13 in GriceLC and 14 in GflaxLC. The mean age was 33 ± 10
years to GriceLC and 40 ± 9 years to GflaxLC. The baseline
clinical, biochemical and dietary characteristics are shown
in Tables 1, 2 and 3 in the time frame marked as initial.
Both groups showed a reduction of approximately 56% of
energy intake compared to baseline.
Blood pressure, anthropometric and biochemical data
Both groups had their anthropometric and systolic blood
pressure measurements reduced (Table 2). Hip circum-
ference reduction was greater in GriceLC group. Weight
loss achieved by GriceLC and GflaxLC were 7 ± 2 and 6 ± 6
kg (mean ± SD), respectively. GriceLC and GflaxLC had
their levels of total cholesterol, LDL cholesterol and uric
acid decreased (Table 3). GflaxLC increased blood levels
of END and ENL, as well as urinary levels of ENL. On
the other hand, GriceLC reduced blood levels of END and
urinary levels of ENL (Figure 2).
Inflammatory markers and hormones
Figure 3 illustrates the changes in inflammatory and hor-
monal markers according to study group and assessment
time. Levels of CRP and TNF-α were reduced (p < 0.05)
only in GflaxLC (mean decrease of 25% and 46% respectively)
Figure 2 Serum and urinary levels of enterodiol and enterolactone according to group and time of assessment. (▲) GriceLC; (●) GflaxLC.
*significant difference between initial and final times (p < 0,05).
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and isoprostane was reduced in both groups. Also, both
groups increased levels of adiponectin (Figure 4).
Discussion
This study shows a decrease in inflammatory markers
(CRP and TNF-α) only in group who received flaxseed,
allowing the assumption yet described in literature that
anti-inflammatory and antiatherogenic activities could
be attributed to components of flaxseed, such as lignans
and its derivatives [23]. Pan et al. showed that dietary
supplementation with capsules of lignans from flaxseed
(360 mg/d) for 12 weeks modulates CRP levels in type II
diabetics when compared to placebo group [24]. The
mechanisms behind these effects could be that glyco-
sides of lignans found in flaxseed are hydrolyzed by
colon bacteria producing bioactive lignans such as enter-
olactone (ENL) and enterodiol (END) [25]. These sub-
stances were found to protect against cardiovascular
disease by decreasing inflammatory response [24,26].
Increases in blood and urinary levels of END and ENL
in the present study indicate absorption of lignans
(Figure 2). Also, antioxidant properties of lignans not
evaluated in our study, like reactive oxygen species scav-
enger, as well as prevention of lipid peroxidation in liver
could be beneficial on human health [6,27].
Inflammation and elevated pro-inflammatory adipo-
kines, such as TNF-α induced by activation of nuclear
factor kappa B, are also associated with excess weight,
especially with increased visceral fat [28,29]. Correlations
have been observed between increased TNF-α and de-
creased anti-inflammatory adipokines, known as adipo-
nectin. These interrelations contribute to long-term
complications such as insulin resistance, endothelial dys-
function and atherosclerosis [30]. In this trial, both
groups increased adiponectin blood levels suggesting
that protection from diseases could be reached by weight
loss in patients with overweight and obesity.
Both groups achieved weight loss and reduction of
waist circumference, as well as other anthropometric
data (Table 2), explained by lower energy intake
(Table 1) [31]. In this matter, we strengthened that to
lose weight, the total intake and negative energy bal-
ance is more important than diet composition itself
[7,12]. Moreover, reduction of blood pressure was
another positive impact on health observed in both
groups, which can be explained by improvements on
weight and central adiposity [32,33].
Figure 3 Serum levels of CRP, TNF-α and isoprostane according
to group and time of assessment. (▲) GriceLC; (●) GflaxLC.
*significant difference between initial and final times (p < 0,05).
Figure 4 Leptin and adiponectin levels according to group and
time of assessment. (▲) GriceLC; (●) GflaxLC. *significant difference
between initial and final times (p < 0,05).
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Other variables, such as total cholesterol, LDL-c and
uric acid also improved in groups GriceLC and GflaxLC.
Reducing carbohydrate intake has been related to ame-
liorated biochemical and hormonal profiles, regardless
weight loss [34,35]. On the other hand, some of these
benefits could be explained by addition of flaxseed, since
some studies have suggested that it reduces hypercholes-
terolemia, hyperinsulinemia, hyperleptinemia as well as
accumulation of visceral fat, specifically in the liver [6].
Serum triglycerides levels only decreased in GflaxLC. A
study with hypercholesterolemic rabbits that consumed
crushed flaxseed also showed reduced serum levels of
LDL-c and triglycerides [36]. GflaxLC received greater
amounts of Omega-3 (Table 1) than GriceLC (14 ± 2 ver-
sus 3 ± 2 g/day, p < 0.01) which suggests that flaxseed
omega 3 fatty acids really contributes to triglyceride re-
duction. In the past, its been suggested that very high
amounts of flaxseed oil, rich in omega 3, would be able
to reduce the triglyceridemia in the same way as fish oil
omega 3 [37]. However, recent reviews did not find any
advantage using flaxseed oil compared to fish oils, as
well as another vegetal oil, in this case, olive [38,39].
One explanation for the absence of evidence of the effect
of flaxseed oil in recent papers is that omega-3 fatty
acids from vegetable oils is alpha-linolenic acid (ALA),
different from fish oils that have, for example, the pro-
moters of effects, eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA). ALA can be converted into
EPA and DHA by the human body, but only in small
fractions (5%), which is why we recommend the con-
sumption of omega-3 from animal origin [40,41]. Finally,
we can not conclude that in our study, the reduction of
triglycerides in GflaxLC was due to flaxseed, weight loss
or reduction of carbohydrates, since due to the small
size of sample, statistical significance in GriceLC was not
achieved. Both groups showed significant reduction in
serum isoprostane. Decrease of this biomarker of lipid
peroxidation occurred in the presence of nutritional
intervention, being essential calorie reduction, consump-
tion of fibers, decrease in body weight and in central
adiposity [42]. This trial has some limitations including
convenience sampling with a small number of subjects
allocated in each group. Therefore, it is not possible war-
rant if the outcomes were related to weight loss, intake
of carbohydrates or flaxseed or a combination of these
interventions.
Conclusion
Despite limitations, this study suggests that in the evalu-
ated population, weight loss diet could be an important
strategy to reduce inflammation markers such as CRP
and TNF-α. Also, flaxseed could contribute to this out-
come. Moreover, reductions observed in blood pressure
and central adiposity could additionally protect against
cardiovascular diseases.
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